Magdalena Meissner

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Sacha J. Howell, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2022 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · Journal of Clinical Oncology · 2022 · 11 citations

Medicine, Oncology, Pharmacology +17

Cytotoxic chemotherapy: clinical aspects

Karam Aboud, Magdalena Meissner, Joanita Ocen et al. · Medicine · 2022 · 11 citations

Medicine, Oncology, Pharmacology +14